FGFR4 Role in Epithelial-Mesenchymal Transition and Its Therapeutic Value in Colorectal Cancer

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Peláez García, Alberto ^a   Barderas, Rodrigo ^a,d   Torres, Sofía ^a   Hernández Varas, Pablo ^a   Teixidó, Joaquín ^a   Bonilla, Félix ^b   de Herreros, Antonio Garcia ^c   Casal, J Ignacio ^a  

^a CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^c HOSPITAL DEL MAR   (Spain)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 4; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN TYROSINE KINASE; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN;

ARTICLE; CANCER CELL; CARCINOGENESIS; CELL ADHESION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; COLON CANCER; COLORECTAL CANCER; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; MICROARRAY ANALYSIS; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PHENOTYPE; TISSUE REPAIR; TUMOR GROWTH;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MICE; MICE, NUDE; POLYMORPHISM, SINGLE NUCLEOTIDE; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4;

EID: 84877831896     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063695     Document Type: Article

References (54)

1. Cronauer MV, Schulz WA, Seifert HH, Ackermann R, Burchardt M, (2003) Fibroblast growth factors and their receptors in urological cancers: basic research and clinical implications. Eur Urol 43: 309-319.
2. Powers CJ, McLeskey SW, Wellstein A, (2000) Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 7: 165-197.
3. Eswarakumar VP, Lax I, Schlessinger J, (2005) Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16: 139-149.
4. Wang J, Stockton DW, Ittmann M, (2004) The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin Cancer Res 10: 6169-6178.
5. Zhao P, Caretti G, Mitchell S, McKeehan WL, Boskey AL, et al. (2006) Fgfr4 is required for effective muscle regeneration in vivo. Delineation of a MyoD-Tead2-Fgfr4 transcriptional pathway. J Biol Chem 281: 429-438.
6. Brooks AN, Kilgour E, Smith PD, (2012) Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res 18: 1855-1862.
7. Babel I, Barderas R, Diaz-Uriarte R, Martinez-Torrecuadrada JL, Sanchez-Carbayo M, et al. (2009) Identification of tumor-associated autoantigens for the diagnosis of colorectal cancer in serum using high density protein microarrays. Mol Cell Proteomics 8: 2382-2395.
8. Barderas R, Babel I, Diaz-Uriarte R, Moreno V, Suarez A, et al. (2012) An optimized predictor panel for colorectal cancer diagnosis based on the combination of tumor-associated antigens obtained from protein and phage microarrays. J Proteomics 75: 4647-4655.
9. Bange J, Prechtl D, Cheburkin Y, Specht K, Harbeck N, et al. (2002) Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res 62: 840-847.
10. Jaakkola S, Salmikangas P, Nylund S, Partanen J, Armstrong E, et al. (1993) Amplification of fgfr4 gene in human breast and gynecological cancers. Int J Cancer 54: 378-382.
11. Ezzat S, Zheng L, Zhu XF, Wu GE, Asa SL, (2002) Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. J Clin Invest 109: 69-78.
12. Ho HK, Pok S, Streit S, Ruhe JE, Hart S, et al. (2009) Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J Hepatol 50: 118-127.
13. Sahadevan K, Darby S, Leung HY, Mathers ME, Robson CN, et al. (2007) Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. J Pathol 213: 82-90.
14. Zhu X, Zheng L, Asa SL, Ezzat S, (2010) Loss of heterozygosity and DNA methylation affect germline fibroblast growth factor receptor 4 polymorphism to direct allelic selection in breast cancer. Am J Pathol 177: 2860-2869.
15. Heinzle C, Gsur A, Hunjadi M, Erdem Z, Gauglhofer C, et al. (2012) Differential effects of polymorphic alleles of FGF receptor 4 on colon cancer growth and metastasis. Cancer Res 72: 5767-5777.
16. Spinola M, Leoni VP, Tanuma J, Pettinicchio A, Frattini M, et al. (2005) FGFR4 Gly388Arg polymorphism and prognosis of breast and colorectal cancer. Oncol Rep 14: 415-419.
17. Taylor JGt, Cheuk AT, Tsang PS, Chung JY, Song YK, et al. (2009) Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest 119: 3395-3407.
18. Spinola M, Leoni V, Pignatiello C, Conti B, Ravagnani F, et al. (2005) Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. J Clin Oncol 23: 7307-7311.
19. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, et al. (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455: 1069-1075.
20. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, et al. (2007) Patterns of somatic mutation in human cancer genomes. Nature 446: 153-158.
21. Stephens P, Edkins S, Davies H, Greenman C, Cox C, et al. (2005) A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet 37: 590-592.
22. Wang J, Yu W, Cai Y, Ren C, Ittmann MM, (2008) Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression. Neoplasia 10: 847-856.
23. Streit S, Bange J, Fichtner A, Ihrler S, Issing W, et al. (2004) Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. Int J Cancer 111: 213-217.
24. Xie MH, Holcomb I, Deuel B, Dowd P, Huang A, et al. (1999) FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine 11: 729-735.
25. Acevedo VD, Ittmann M, Spencer DM, (2009) Paths of FGFR-driven tumorigenesis. Cell Cycle 8: 580-588.
26. Nicholes K, Guillet S, Tomlinson E, Hillan K, Wright B, et al. (2002) A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol 160: 2295-2307.
27. Desnoyers LR, Pai R, Ferrando RE, Hotzel K, Le T, et al. (2008) Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 27: 85-97.
28. Yang C, Jin C, Li X, Wang F, McKeehan WL, et al. (2012) Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. PLoS One 7: e33870.
29. Gagos S, Hopwood VL, Iliopoulos D, Kostakis A, Karayannakos P, et al. (1995) Chromosomal markers associated with metastasis in two colon cancer cell lines established from the same patient. Anticancer Res 15: 369-378.
30. Leibovitz A, Stinson JC, McCombs WB 3rd, McCoy CE, Mazur KC, et al (1976) Classification of human colorectal adenocarcinoma cell lines. Cancer Res 36: 4562-4569.
31. Morikawa K, Walker SM, Jessup JM, Fidler IJ, (1988) In vivo selection of highly metastatic cells from surgical specimens of different primary human colon carcinomas implanted into nude mice. Cancer Res 48: 1943-1948.
32. Morikawa K, Walker SM, Nakajima M, Pathak S, Jessup JM, et al. (1988) Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice. Cancer Res 48: 6863-6871.
33. Trudel S, Ely S, Farooqi Y, Affer M, Robbiani DF, et al. (2004) Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood 103: 3521-3528.
34. Lee SH, Lopes de Menezes D, Vora J, Harris A, Ye H, et al. (2005) In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin Cancer Res 11: 3633-3641.
35. Barderas R, Bartolome RA, Fernandez-Acenero MJ, Torres S, Casal JI, (2012) High Expression of IL-13 Receptor alpha2 in Colorectal Cancer Is Associated with Invasion, Liver Metastasis, and Poor Prognosis. Cancer Res 72: 2780-2790.
36. Ruhe JE, Streit S, Hart S, Wong CH, Specht K, et al. (2007) Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines. Cancer Res 67: 11368-11376.
37. Scheel C, Eaton EN, Li SH, Chaffer CL, Reinhardt F, et al. (2011) Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 145: 926-940.
38. Timmerman P, Barderas R, Desmet J, Altschuh D, Shochat S, et al. (2009) A combinatorial approach for the design of complementarity-determining region-derived peptidomimetics with in vitro anti-tumoral activity. J Biol Chem 284: 34126-34134.
39. Barderas R, Shochat S, Timmerman P, Hollestelle MJ, Martinez-Torrecuadrada JL, et al. (2008) Designing antibodies for the inhibition of gastrin activity in tumoral cell lines. Int J Cancer 122: 2351-2359.
40. FitzGerald LM, Karlins E, Karyadi DM, Kwon EM, Koopmeiners JS, et al. (2009) Association of FGFR4 genetic polymorphisms with prostate cancer risk and prognosis. Prostate Cancer Prostatic Dis 12: 192-197.
41. Nan H, Qureshi AA, Hunter DJ, Han J, (2009) Genetic variants in FGFR2 and FGFR4 genes and skin cancer risk in the Nurses' Health Study. BMC Cancer 9: 172.
42. Auguste P, Gursel DB, Lemiere S, Reimers D, Cuevas P, et al. (2001) Inhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and-independent mechanisms. Cancer Res 61: 1717-1726.
43. Martinez-Torrecuadrada J, Cifuentes G, Lopez-Serra P, Saenz P, Martinez A, et al. (2005) Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation. Clin Cancer Res 11: 6280-6290.
44. Martinez-Torrecuadrada JL, Cheung LH, Lopez-Serra P, Barderas R, Canamero M, et al. (2008) Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis. Mol Cancer Ther 7: 862-873.
45. Trudel S, Stewart AK, Rom E, Wei E, Li ZH, et al. (2006) The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood 107: 4039-4046.
46. Greulich H, Pollock PM, (2011) Targeting mutant fibroblast growth factor receptors in cancer. Trends Mol Med 17: 283-292.
47. Babel I, Barderas R, Diaz-Uriarte R, Moreno V, Suarez A, et al. (2011) Identification of MST1/STK4 and SULF1 proteins as autoantibody targets for the diagnosis of colorectal cancer by using phage microarrays. Mol Cell Proteomics.
48. Thiery JP, Acloque H, Huang RY, Nieto MA, (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890.
49. Acevedo VD, Gangula RD, Freeman KW, Li R, Zhang Y, et al. (2007) Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell 12: 559-571.
50. Tomlinson DC, Baxter EW, Loadman PM, Hull MA, Knowles MA, (2012) FGFR1-Induced Epithelial to Mesenchymal Transition through MAPK/PLCgamma/COX-2-Mediated Mechanisms. PLoS One 7: e38972.
51. Chaffer CL, Brennan JP, Slavin JL, Blick T, Thompson EW, et al. (2006) Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res 66: 11271-11278.
52. de Frutos CA, Vega S, Manzanares M, Flores JM, Huertas H, et al. (2007) Snail1 is a transcriptional effector of FGFR3 signaling during chondrogenesis and achondroplasias. Dev Cell 13: 872-883.
53. Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, et al. (2005) CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 105: 2941-2948.
54. French DM, Lin BC, Wang M, Adams C, Shek T, et al. (2012) Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS One 7: e36713.